Co-Authors
This is a "connection" page, showing publications co-authored by SIMONA COLLA and GUILLERMO GARCIA-MANERO.
Connection Strength
4.892
-
The IL-1? inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial. Nat Commun. 2024 Nov 13; 15(1):9840.
Score: 0.248
-
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Rep Med. 2024 Jun 18; 5(6):101585.
Score: 0.240
-
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun. 2024 Mar 18; 15(1):2428.
Score: 0.237
-
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nat Commun. 2024 Feb 08; 15(1):1203.
Score: 0.236
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
Score: 0.235
-
IL-1?-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes. bioRxiv. 2023 Sep 30.
Score: 0.230
-
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv. 2023 Apr 08.
Score: 0.222
-
Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma. bioRxiv. 2023 Feb 22.
Score: 0.220
-
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Rep Med. 2023 02 21; 4(2):100940.
Score: 0.220
-
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov. 2022 11 02; 3(6):554-567.
Score: 0.216
-
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022 Oct; 9(10):e756-e765.
Score: 0.213
-
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia. 2022 08; 36(8):2097-2107.
Score: 0.210
-
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 May; 28(5):1097.
Score: 0.208
-
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 03; 28(3):557-567.
Score: 0.206
-
Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021 11 25; 12(1):6850.
Score: 0.202
-
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933.
Score: 0.168
-
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv. 2018 10 09; 2(19):2491-2504.
Score: 0.163
-
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6.
Score: 0.149
-
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
Score: 0.145
-
PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S67-73.
Score: 0.140
-
Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res. 2016 May; 44:1-7.
Score: 0.136
-
Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma. 2015; 56(12):3426-33.
Score: 0.129
-
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57.
Score: 0.128
-
Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations. Blood. 2024 Dec 05; 144(23):2402-2416.
Score: 0.062
-
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Sci Transl Med. 2024 Sep 11; 16(764):eadp0004.
Score: 0.061
-
Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv. 2024 May 24.
Score: 0.060
-
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
Score: 0.039
-
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017 01; 18(1):100-111.
Score: 0.036
-
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. Cell Rep. 2015 Nov 03; 13(5):1033-45.
Score: 0.033
-
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31; 5:e333.
Score: 0.033
-
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5.
Score: 0.032
-
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 2015 Jul; 29(7):1458-69.
Score: 0.032